This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Delgado, M. R. Articles by Roach, E. S. Search for Related Content PubMed PubMed Citation Articles by Delgado, M. R. Articles by Roach, E. S. Social Bookmarking                         What's this?

Thrombocytopenia Secondary to High Valproate Levels in Children With Epilepsy

Department of Neurology University of Texas Southwestern Medical Center at Dallas, Texas Scottish Rite Hospital for Children

Anthony R. Riela, MD

Department of Neurology University of Texas Southwestern Medical Center at Dallas, Children's Medical Center at Dallas

Janith Mills, PA-C

Texas Scottish Rite Hospital for Children Dallas, TX

Richard Browne, PhD

Texas Scottish Rite Hospital for Children Dallas, TX

E. Steven Roach, MD

Department of Neurology University of Texas Southwestern Medical Center at Dallas, Children's Medical Center at Dallas

We reviewed the frequency of valproate-induced thrombocytopenia in children with epilepsy in our institution. Sixty-four (21%) of 306 children taking valproate developed thrombocytopenia. Thirty-two of these 64 patients had at least one platelet count lower than 100 x 10³/mm³. Eight patients developed signs of bleeding. Low platelet levels were typically noted in patients with serum valproate levels of over 140 µg/mL, and reduction of the medication dose usually resulted in a prompt increase in the number of platelets. Only one patient developed thrombocytopenia unrelated to high serum drug levels, and her platelet count did not improve until the drug was discontinued. Neither the age of the patient nor the use of additional antiepileptic medication correlated with the platelet count. However, duration of valproate use was related. These data suggest that, although valproate may cause thrombocytopenia via more than one mechanism, by far the most common factor is the presence of high valproate levels. Thus, the medication can be safely lowered in most patients with thrombocytopenia rather than discontinued altogether. Platelet counts should probably be monitored more carefully in patients known to have higher drug levels. (J Child Neurol 1994;9:311-314).

Journal of Child Neurology, Vol. 9, No. 3, 311-314 (1994)
DOI: 10.1177/088307389400900318


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P. J. Morris Compliance Profile of Depakote ER Compared to Depakote DR and Valproic Acid in Bipolar Patients Journal of Correctional Health Care, October 1, 2008; 14(4): 311 - 317. [Abstract] [PDF]

				G. Serdaroglu, S. Tutuncuoglu, K. Kavakli, and H. Tekgiil Coagulation Abnormalities and Acquired von Willebrand's Disease Type 1 in Children Receiving Valproic Acid J Child Neurol, January 1, 2002; 17(1): 41 - 43. [Abstract] [PDF]

				R. W. LOVELL Mood Stabilizer Combinations for Bipolar Disorder Am J Psychiatry, June 1, 1999; 156(6): 980a - 980. [Full Text]

				R. Selby, E. Nisbet-Brown, R. K. Basran, L. Chang, and N. F. Olivieri Valproic Acid and Augmentation of Fetal Hemoglobin in Individuals With and Without Sickle Cell Disease Blood, July 15, 1997; 90(2): 891 - 892. [Full Text] [PDF]

				D. A. Tam Jr and E. C. Myer Vitamin K-Dependent Coagulopathy in a Child Receiving Anticonvulsant Therapy J Child Neurol, May 1, 1996; 11(3): 244 - 246. [PDF]